

NeuroSense Investor Relations

NeuroSense CEO Provides Q2 2023 Update

View video here: [Link](#)

CAMBRIDGE, Mass., July 6, 2023 /PRNewswire/ -- [NeuroSense Therapeutics Ltd.](#) (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments during the second quarter of 2023.